These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 9800809

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.
    Harker LA, Marzec UM, Novembre F, Sundell IB, Waller EK, Karpatkin S, McClure HM, Kelly AB, Stead RB.
    Blood; 1998 Jun 15; 91(12):4427-33. PubMed ID: 9616135
    [Abstract] [Full Text] [Related]

  • 24. Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice.
    Akahori H, Ozai M, Ida M, Shibuya K, Kato T, Miyazaki H.
    Ther Apher; 1998 Feb 15; 2(1):58-64. PubMed ID: 10227790
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H, Shibuya K, Ozai M, Ida M, Kabaya K, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov 15; 14(6):678-89. PubMed ID: 8948025
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitization.
    Nash RA, Takatu A, Feng Z, Slichter S, Abrams K, Espino G, Gass MJ, Georges GE, McSweeney PA, Shulman HM, Storb R.
    Biol Blood Marrow Transplant; 2002 Nov 15; 8(7):360-7. PubMed ID: 12171482
    [Abstract] [Full Text] [Related]

  • 31. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
    Molineux G, Hartley C, McElroy P, McCrea C, Kerzic P, McNiece I.
    Stem Cells; 1997 Nov 15; 15(1):43-9. PubMed ID: 9007221
    [Abstract] [Full Text] [Related]

  • 32. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
    Ide Y, Harada K, Imai A, Yanagida M.
    Int J Hematol; 1999 Aug 15; 70(2):91-6. PubMed ID: 10497847
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans.
    De Boer RH, Roskos LK, Cheung E, Fox S, Basser RL, Marty J, Begley CG, Cebon J.
    Growth Factors; 2000 Aug 15; 18(3):215-26. PubMed ID: 11334057
    [Abstract] [Full Text] [Related]

  • 35. Reactivity of platelets from healthy individuals and from patients with hematologic diseases following incubation with pegylated recombinant human megakaryocyte growth and development factor in vitro.
    Matzdorff AC, Kemkes-Matthes B, Pralle H.
    Haemostasis; 1998 Aug 15; 28(1):37-44. PubMed ID: 9885369
    [Abstract] [Full Text] [Related]

  • 36. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
    Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L.
    N Engl J Med; 1997 Feb 06; 336(6):404-9. PubMed ID: 9010146
    [Abstract] [Full Text] [Related]

  • 37. The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia.
    Adams JA, Liu Yin JA, Brereton ML, Briggs M, Burgess R, Hyde K.
    Br J Haematol; 1997 Oct 06; 99(1):139-46. PubMed ID: 9359514
    [Abstract] [Full Text] [Related]

  • 38. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.
    Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, Heil G, Fenaux P, Brugger W, Barge A, O'Brien-Ewen C, Matcham J, Hoelzer D.
    Blood; 1999 Dec 01; 94(11):3694-701. PubMed ID: 10572081
    [Abstract] [Full Text] [Related]

  • 39. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
    Basser RL.
    Stem Cells; 1998 Dec 01; 16 Suppl 2():225-9. PubMed ID: 11012194
    [Abstract] [Full Text] [Related]

  • 40. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
    Sheridan W, Menchaca D.
    Stem Cells; 1998 Dec 01; 16 Suppl 2():193-8. PubMed ID: 11012191
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.